Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

NCT01874626 | Completed Phase 3

• 1 other identifier: SST0225-US-010-001
• Study Type: interventional
• Target: 305
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.

Conditions

Acute Ankle Sprain

Keywords

acute ankle sprain; Grade I or Grade II

Outcome Measures

Primary Outcomes (1)

• 24 Hour SPID

  Tme weighted summed pain intensity on movement difference from baseline over the first 24 hours (SPID24) following the first application of study medication on Day 1

  24 Hours

Secondary Outcomes (8)

• Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief

  First 4 hours

• Mean change from baseline in subject reported pain intensity

  First 4 hours

• Mean change from baseline in pain scores on movement

  First 24 hours

• Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity

  First 24 hours

• Subject's global evaluation of investigational product

  7 days

Study Arms (2)

Active

ACTIVE COMPARATOR

SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen

Drug: SST-0225 Topical Ibuprofen Cream

Placebo

PLACEBO COMPARATOR

Placebo topical formulation (Reference product)

Drug: Placebo

Interventions

Placebo DRUG

Placebo cream

Placebo

SST-0225 Topical Ibuprofen Cream DRUG

SST-0225 Topical Ibuprofen Cream

Also known as: Ibuprofen

Active

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects ≥16 years of age
• Grade I or II acute ankle sprain injury within 24 hours prior to first use of investigational product.
• Grade I: when the ligament is stretched but not torn and the anterior talofibular ligament is usually involved. The anterior drawer test is negative
• Grade II: moderate sprain, which usually results in partial tears of the ligaments, primarily the anterior talofibular and possibly the calcaneofibular ligament. Ligamentous laxity may be present and there is moderate swelling
• At screening (Visit 1), subject reported pain intensity score upon movement of ≥ 5 on a 0-10 Numerical Rating Scale (NRS)
• Subject's Assessment of Normal Function/Activity (must be \> 2) at screening
• Able to comply with the visit schedule
• Able to apply the investigational product as directed
• Females of childbearing potential must be willing to use an approved method of birth control during study participation. Subjects currently using any of the below mentioned contraception methods, must have used the method for a minimum of three months prior to study enrollment, and must be willing to continue its use (at the same dose) throughout the study.
• Effective methods of birth control: e.g. prescription oral, vaginal or transdermal contraceptives; contraceptive implants or injections; intrauterine device; diaphragm/cervical cap/condom with spermicide
• Other acceptable methods of birth control include: Postmenopausal or amenorrhea for one year, Surgically sterile (hysterectomy, tubal ligation, or oopherectomy), Premenarcheal
• Able to speak, read and comprehend English and record requested measurements as outlined in the protocol
• Subject must be able to read, understand, sign and date the informed consent document (and the subject assent form, if necessary) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial

You may not qualify if:

• Subjects meeting any of the following criteria will not be entered in the study:
• Similar injury of the same joint within the last 6 months
• Clinical evidence of complete rupture of ankle ligaments (third degree sprain)
• Requirements for bed rest, hospitalization, or surgical intervention for the ankle injury
• Evidence of fractures or non-removable full cast of any type
• Presence of bilateral occurrence of ankle injury or ipsilateral ankle and/or knee injury
• Open wound or infection at site of injury
• Significant Skin irritation at the application site;
• Use of longer half life NSAID within 12 hours prior to study entry (Appendix 4)
• Does not agree to use only supplied investigational product and rescue medication for analgesia during the seven days of the study or expects to require analgesics during the study for pain other than for ankle pain
• Presence or history of allergy or intolerance to aspirin, NSAIDs, acetaminophen or any of the excipients in the investigational product (L-Arginine hydrochloride, Glyceryl Stearate, Cetyl Alcohol, Squalane, Xanthan Gum, Isopropyl Myristate, Oleic Acid, Propylene Glycol, Polysorbate -20)
• Medical conditions including: peptic ulcer disease; clinically important gastrointestinal, renal, or hepatic disease within the past 6 months; clinically significant cardiovascular disease not stable for the past 6 months; uncontrolled hypertension as indicated by systolic blood pressure greater than or equal to 160 mmHg or a diastolic blood pressure greater than or equal to 100 mm Hg; coagulation disorders or hematologic disease; history of seizures; or known, significant, pre-existing conditions that would affect the interpretation of any potential adverse reactions to the study medication
• Known alcohol abuse, drug dependency, or history of significant psychiatric illness within the past 12 months
• Females who are pregnant or lactating.

Sponsors & Collaborators

• Strategic Science & Technologies, LLC: lead

Study Sites (1)

Ce3

Guilford, Connecticut, 06437, United States

Location

MeSH Terms

Conditions

Lymphoma, Follicular

Interventions

Ibuprofen

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Phenylpropionates; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 11, 2012
• First Posted: June 11, 2013
• Study Start: June 1, 2013
• Primary Completion: January 1, 2014
• Study Completion: January 1, 2014
• Last Updated: May 21, 2021

Record last verified: 2014-01

Locations

US (1)